These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27054544)

  • 21. Treatment of chronic delta hepatitis.
    Yurdaydin C
    Semin Liver Dis; 2012 Aug; 32(3):237-44. PubMed ID: 22932972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
    Formann E; Steindl-Munda P; Hofer H; Jessner W; Bergholz U; Gurguta C; Ferenci P
    Aliment Pharmacol Ther; 2006 Feb; 23(4):507-11. PubMed ID: 16441471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
    Niro GA; Ciancio A; Gaeta GB; Smedile A; Marrone A; Olivero A; Stanzione M; David E; Brancaccio G; Fontana R; Perri F; Andriulli A; Rizzetto M
    Hepatology; 2006 Sep; 44(3):713-20. PubMed ID: 16941685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
    Akhan SC; Gurel E; Sayan M
    Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months.
    Ormeci N; Bölükbaş F; Erden E; Coban S; Ekiz F; Erdem H; Palabıyıkoğlu M; Beyler AR; Balık I; Bölükbaş C; Nazlıgül Y; Köklü S
    Hepatogastroenterology; 2011; 58(110-111):1648-53. PubMed ID: 22086695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
    Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon.
    Yurdaydin C; Bozkaya H; Onder FO; Sentürk H; Karaaslan H; Akdoğan M; Cetinkaya H; Erden E; Erkan-Esin O; Yalçin K; Bozdayi AM; Schinazi RF; Gerin JL; Uzunalimoğlu O; Ozden A
    J Viral Hepat; 2008 Apr; 15(4):314-21. PubMed ID: 18307594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
    Saracco G; Olivero A; Ciancio A; Carenzi S; Smedile A; Cariti G; Andreoni M; Orsi PG; Biglino A; Tabone M; Roffi L; Croce G; Manca A; Tappero G; Ciccone G; Rizzetto M
    Hepatology; 2002 Oct; 36(4 Pt 1):959-66. PubMed ID: 12297844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entecavir treatment of chronic hepatitis D.
    Kabaçam G; Onder FO; Yakut M; Seven G; Karatayli SC; Karatayli E; Savas B; Idilman R; Bozdayi AM; Yurdaydin C
    Clin Infect Dis; 2012 Sep; 55(5):645-50. PubMed ID: 22573857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment.
    Mederacke I; Yurdaydin C; Dalekos GN; Bremer B; Erhardt A; Cakaloglu Y; Yalcin K; Gurel S; Zeuzem S; Zachou K; Bozkaya H; Dienes HP; Manns MP; Wedemeyer H;
    Antivir Ther; 2012; 17(2):305-12. PubMed ID: 22293066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial.
    Canbakan B; Senturk H; Tabak F; Akdogan M; Tahan V; Mert A; Sut N; Ozaras R; Midilli K; Ozbay G
    J Gastroenterol Hepatol; 2006 Apr; 21(4):657-63. PubMed ID: 16677149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of low-dose interferon therapy for treating chronic hepatitis C patients who cannot tolerate standard treatment].
    Cao ZH; Liu YL; Zheng YH; Ji SD; Wang JL; Liao JH; Zhang CY; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):20-4. PubMed ID: 22464701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
    Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çalişkan A; Karatayli E; Karatayli S; Bozdayi AM; Koh C; Heller T; Idilman R; Glenn JS
    Hepatology; 2018 Apr; 67(4):1224-1236. PubMed ID: 29152762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
    Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
    J Med Virol; 2013 Jan; 85(1):65-70. PubMed ID: 23154876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience.
    Bahcecioglu IH; Ispiroglu M; Demirel U; Yalniz M
    Hepat Mon; 2015 Mar; 15(3):e24366. PubMed ID: 25861318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study: longer duration of posttransplant hepatitis C virus therapy may increase the sustained response rate.
    Karasu Z; Akay S; Yilmaz F; Akarca U; Ersoz G; Gunsar F; Kilic M
    Transplant Proc; 2009 Nov; 41(9):3806-9. PubMed ID: 19917392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study.
    Niro GA; Ciancio A; Tillman HL; Lagget M; Olivero A; Perri F; Fontana R; Little N; Campbell F; Smedile A; Manns MP; Andriulli A; Rizzetto M
    Aliment Pharmacol Ther; 2005 Aug; 22(3):227-32. PubMed ID: 16091060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.